Special SRT Distinction Now Available to ACR-Accredited Practices

Press Release
Article

ACR-accredited radiation oncology practices will now be eligible to apply for an advanced quality recognition program developed by ACRO and RSS.

The program was designed by professional peers with extensive experience treating patients with SRS/SBRT, with the aim to identify standards indicative of a quality practice in the field of SRS/SBRT.

The program was designed by professional peers with extensive experience treating patients with SRS/SBRT, with the aim to identify standards indicative of a quality practice in the field of SRS/SBRT.

The American College of Radiation Oncology (ACRO) and the Radiosurgery Society (RSS) have announced that the Special Distinction in Stereotactic Radiotherapy (SRT) will be available to radiation oncology practices accredited through the American College of Radiology® (ACR®). Through the agreement, ACR-accredited radiation oncology practices will be eligible to apply for the SRT Distinction: an advanced quality recognition program jointly developed by ACRO and RSS.

Through this agreement, ACR-accredited radiation oncology practices will now be eligible to apply for the SRT Distinction: an advanced quality recognition program jointly developed by ACRO and RSS. Previously, the distinction was available exclusively to ACRO-accredited practices.

“This distinction allows ACR ROPA sites to enhance their stereotactic programs—not only adding another layer of quality and safety—but showing their patients that they are going above and beyond to excel in patient care," said David C. Beyer, MD, FACR, chair of the American College of Radiology Commission on Radiation Oncology. “As the indications, techniques, and technologies for stereotactic radiation grow, this affiliation between ACRO, RSS and ACR will recognize those programs that truly maintain the state of the art in SRS/SBRT.”

Click here for more information on the Special Distinction in Stereotactic Radiotherapy, including how to apply.

Recent Videos
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
Related Content
A total of 61.86% of patients with LACSCC treated with the nimotuzumab-based regimen in the phase 2 trial achieved a complete response.

Nimotuzumab Plus Image-Guided RT May Be Feasible in Older LACSCC Population

Roman Fabbricatore
November 17th 2025
Article
A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Noninvasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Establishing guideline harmonization and practice standardization may help promote the safe and consistent delivery of radiopharmaceutical therapies.

Leveraging Multidisciplinary Collaboration to Enhance RPT Benefit in Cancer

Roman Fabbricatore
November 12th 2025
Article

Establishing guideline harmonization and practice standardization may help promote the safe and consistent delivery of radiopharmaceutical therapies.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Short-Course Radiation May Be Feasible in Older Rectal Cancer Population

Russ Conroy
November 3rd 2025
Article

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Combinations of anti-angiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis

Tim Cortese
October 31st 2025
Article

Combinations of antiangiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.